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 Purpose: To prospectively compare the image quality and diagnostic per-
formance achieved with doses of gadobenate dimeglumine and 
gadopentetate dimeglumine of 0.1 mmol per kilogram of body 
weight in patients undergoing contrast material–enhanced mag-
netic resonance (MR) angiography of the pelvis, thigh, and lower-
leg (excluding foot) for suspected or known peripheral arterial 
occlusive disease.
 Materials and 
Methods: 
Institutional review board approval was granted from each center 
and informed written consent was obtained from all patients. Be-
tween November 2006 and January 2008, 96 patients (62 men, 34 
women; mean age, 63.7 years  6 10.4 [standard deviation]; range, 
39–86 years) underwent two identical examinations at 1.5 T by 
using three-dimensional spoiled gradient-echo sequences and ran-
domized 0.1-mmol/kg doses of each agent. Images were evaluated 
on-site for technical adequacy and quality of vessel visualization 
and offsite by three independent blinded readers for anatomic de-
lineation and detection/exclusion of pathologic features. Compara-
tive diagnostic performance was determined in 31 patients who 
underwent digital subtraction angiography. Data were analyzed 
by using the Wilcoxon signed-rank, McNemar, and Wald tests. 
Interreader agreement was determined by using generalized  k 
statistics. Differences in quantitative contrast enhancement were 
assessed and a safety evaluation was performed.
 Results: Ninety-two patients received both agents. Signifi cantly better per-
formance ( P  , .0001; all evaluations) with gadobenate dimeglumine 
was noted on-site for technical adequacy and vessel visualization 
quality and offsite for anatomic delineation and detection/exclusion 
of pathologic features. Contrast enhancement ( P   .0001) and de-
tection of clinically relevant disease ( P   .0028) were signifi cantly 
improved with gadobenate dimeglumine. Interreader agreement 
for stenosis detection and grading was good to excellent ( k = 0.749 
and 0.805, respectively). Mild adverse events were reported for 
four (six events) and fi ve (eight events) patients after gadobenate 
dimeglumine and gadopentetate dimeglumine, respectively.
 Conclusion: Higher-quality vessel visualization, greater contrast enhance-
ment, fewer technical failures, and improved diagnostic perfor-
mance are obtained with gadobenate dimeglumine, relative to 
gadopentetate dimeglumine, when compared intraindividually at 
0.1-mmol/kg doses in patients undergoing contrast-enhanced MR 
angiography for suspected peripheral arterial occlusive disease.
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phy for suspected or known peripheral 
arterial occlusive disease. 
 Materials and Methods 
 Our phase III, double-blind, multi-
center, randomized, intraindividual 
crossover comparison was sponsored by 
Bracco Imaging (Milan, Italy) and was 
registered at www.clintrials.gov (ref. 
00408083). Institutional review board 
and regulatory approval were granted 
from each center and all patients gave 
written informed consent. Two au-
thors (M.A.K. and G.P.) are employees 
of Bracco Imaging. The lead authors 
(S.C.G. and T.L.) had complete access 
to all study results, and all authors had 
full control of the data and statistical 
results included in this report, includ-
ing data that might have represented a 
potential confl ict of interest to Bracco 
and employees thereof. 
 Patients 
 Ninety-six adult patients with suspected 
moderate to severe peripheral arterial 
occlusive disease, determined on the 
basis of the Fontaine classifi cation ( 30 ), 
were enrolled at seven sites in Europe 
between November 2006 and January 
2008. Centers enrolled 25, 25, 15, 11, 
nine, seven, and four patients. 
( 15–18 ). This is particularly relevant for 
elderly patients with peripheral arterial 
occlusive disease, not only because of 
the high gadolinium doses routinely ad-
ministered, but also because these pa-
tients frequently have associated renal 
insuffi ciency or end-stage renal disease 
( 19,20 ). 
 Gadobenate dimeglumine (Multi-
Hance; Bracco Imaging, Milan, Italy) is 
a gadolinium-based contrast agent ap-
proved in Europe, Canada, and elsewhere 
for contrast-enhanced MR angiography 
at a dose of 0.1 mmol per kilogram of 
body weight. Compared with conven-
tional agents, gadobenate dimeglumine 
possesses increased R1 relaxivity ( 21–
25 ), which permits lower overall doses 
to achieve similar contrast enhance-
ment and equivalent image quality to 
that achieved with conventional agents 
at higher doses ( 26,27 ). Previously, a 
comparison of equivalent 0.1-mmol/kg 
doses of gadobenate dimeglumine and 
gadopentetate dimeglumine (Magnev-
ist; Bayer-Schering, Berlin, Germany) 
in healthy volunteers revealed superior 
vascular enhancement with gadobenate 
dimeglumine, particularly in smaller, 
more distal vessels ( 28 ). Improved di-
agnostic performance with gadobenate 
dimeglumine for below-knee segments 
was subsequently shown by Wyttenbach 
et al ( 29 ) in a comparison with gadot-
erate meglumine. However, Wyttenbach 
et al administered a standard volume 
of 34 mL, which corresponds to a high 
dose of almost 0.25 mmol/kg for a 
70-kg person. 
 Our prospective study was per-
formed to compare the image quality 
and diagnostic performance achieved 
with equivalent 0.1-mmol/kg doses of 
gadobenate dimeglumine and gadopen-
tetate dimeglumine in patients under-
going contrast-enhanced MR angiogra-
 Contrast material–enhanced MR angiography is an accepted non-invasive alternative to conven-
tional digital subtraction angiography 
(DSA) for assessment of peripheral 
arterial occlusive disease ( 1–5 ). How-
ever, a drawback of contrast-enhanced 
MR angiography is insuffi cient contrast 
enhancement for accurate visualization 
and diagnosis if the contrast agent dose 
is too low ( 6–9 ). This is particularly 
relevant in the peripheral runoff vas-
culature where vessels are smaller and 
highly susceptible to fl ow alterations in 
heavily diseased patients; it is also rel-
evant if parallel imaging techniques are 
used because these techniques decrease 
the signal-to-noise ratio (SNR) ( 10 ). 
 One approach to improving SNR 
is to increase the contrast agent dose 
( 11–14 ). Unfortunately, high gadolinium 
doses are inadvisable because of the 
risk of nephrogenic systemic fi brosis 
 Implication for Patient Care 
 In most patients, a dose of 0.1  n
mmol/kg of gadobenate dimeglu-
mine is suffi cient for adequate 
depiction of the peripheral arte-
rial tree from the pelvis to the 
calves. 
 Advances in Knowledge 
 For contrast material–enhanced  n
MR angiography of peripheral 
arterial vasculature from the 
pelvis to the calves, a dose of 0.1 
mmol/kg of gadobenate dimeglu-
mine is superior to an equivalent 
dose of gadopentetate dimeglu-
mine in terms of quality of vessel 
visualization ( P  , .0001), techni-
cal failure rate ( P  , .0001), and 
level of contrast enhancement 
( P  , .0001). 
 Signifi cantly improved detection  n
( P   .0017) of clinically relevant 
stenoses ( . 50% vessel lumen 
narrowing) is achieved with 0.1 
mmol/kg of gadobenate dimeglu-
mine compared with 0.1 mmol/
kg of gadopentetate dimeglu-
mine, relative to digital subtrac-
tion angiography. 
 Signifi cant increases (  n P  , .0001) 
in contrast-to-noise ratios of 
45.0%–59.6% in the pelvis, 
55.4%–100.6% in the thigh, and 
49.2%–66.5% in the calf are 
achieved with 0.1 mmol/kg of 
gadobenate dimeglumine relative 
to 0.1 mmol/kg of gadopentetate 
dimeglumine. 
 Published online 
 10.1148/radiol.09090357 
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 Abbreviations: 
 CNR = contrast-to-noise ratio 
 DSA = digital subtraction angiography 
 SI = signal intensity 
 SNR = signal-to-noise ratio 
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 Contrast-enhanced MR angiography 
was performed after administration of 
a dose of 0.1 mmol/kg (0.2 mL/kg of 
the available 0.5-mol formulation) gad-
obenate dimeglumine or gadopentetate 
dimeglumine. Injections were either 
monophasic ( n = 34) at 1–3 mL/sec 
or biphasic ( n = 62), administered at 
1–1.5 mL/sec for the fi rst injection and 
0.5–0.8 mL/sec for the second. The in-
jection scheme was identical for both 
examinations in each patient and were 
performed with a power injector (Me-
drad, Indianola, PA) and fl ushed with 
20 mL of saline. 
 Timing for the contrast-enhanced 
MR angiography sequence was based 
on a bolus timing acquisition in 53 sub-
jects or by means of automatic bolus 
detection (Bolus Trak, Philips Medical 
Systems [ n = 36]; MR fl uoroscopic trig-
gering [ n = 7]). The approach to se-
quence timing was the same for both 
examinations in each patient. 
 MR Angiographic Assessment 
 On-site assessment.— Unpaired assess-
ments were performed by on-site inves-
tigators (S.C.G., T.M., S.M., S.A.T., 
C.U.H., H.J.M., H.K., and T.L., 
each with   8 years experience with 
sets. Both examinations in each patient 
were identical with respect to orienta-
tion, fi eld-of-view, sequence parameters, 
spatial resolution, and contrast agent 
volume and injection rate. The interval 
between examinations in each patient 
ranged between 3 and 13 days, although 
in most patients ( n = 86), the interval 
between examinations ranged between 
4 and 7 days. 
 Each examination comprised an 
unenhanced three-dimensional spoiled 
gradient-echo (mask) sequence and a 
contrast-enhanced three-dimensional 
spoiled gradient-echo sequence. The 
sequence parameters necessarily var-
ied slightly between centers because 
of the variety of imaging systems 
utilized; however, each sequence ob-
tained at each center was selected to 
meet minimal requirements for image 
acquisition and interpretability. The 
range of parameters for each station 
is shown in  Table 1 . Parallel imag-
ing techniques and fat suppression 
were recommended. Timing for table 
translation from one station to the 
next was determined by the duration 
of the acquisition for each station and 
was identical for both examinations in 
each patient. 
 Patients with moderate to severe 
renal impairment (glomerular fi ltration 
rate or estimated glomerular fi ltration 
rate,  , 60 mL/min/1.73 m 2 ), conges-
tive heart failure (New York Heart 
Association functional class IV), or 
a known allergy to either agent were 
considered as ineligible and were not 
enrolled. Patients were also ineligible 
if they had received or were scheduled 
to receive another contrast medium 
in the 24 hours preceding and until 
24 hours following either examination, 
any other investigational compound 
and/or medical device within 30 days 
before and until 24 hours after admin-
istration of the second agent, or were 
scheduled to undergo any intervention 
for peripheral arterial occlusive dis-
ease between the two examinations. 
Finally, patients were ineligible if they 
were pregnant or lactating or if they 
had any medical condition or other 
circumstances (eg, metallic vascular 
stent, pacemaker, severe claustropho-
bia) that would decrease the chances 
of obtaining adequate examination re-
sults or which would preclude proxim-
ity to a strong magnetic fi eld. 
 Eligible patients were randomized 
prospectively to two groups (A and B). 
Group A ( n = 52) received gadobenate 
dimeglumine for the fi rst examination 
and gadopentetate dimeglumine for the 
second; patients in group B ( n = 44) 
received the contrast agents in reverse 
order ( Fig 1 ). 
 MR Angiographic Examinations 
 All procedures were performed at 1.5 
T by using commercially available im-
agers (Avanto [ n = 37], Siemens Medi-
cal Solutions, Erlangen, Germany; and 
Intera [ n = 25], Achieva [ n = 25], and 
Gyroscan Intera [ n = 9], Philips Medi-
cal Systems, Best, the Netherlands) 
equipped with a gradient of at least 
30 mT/m and an automatic moving 
table. 
 Peripheral arterial vasculature from 
the aortic bifurcation to the lower leg 
was imaged in three stations comprising 
the pelvis, thigh, and calf (excluding the 
foot). To ensure complete coverage of 
each station, images were acquired with 
a small overlap between consecutive data 
 Figure 1 
  
 Figure 1: Flow diagram of patient enrollment and evaluation.  AE = adverse event,  CM = contrast medium. 
Radiology: Volume 255: Number 3—June 2010 n radiology.rsna.org 991
 VASCULAR AND INTERVENTIONAL RADIOLOGY: Contrast Material Comparison for MR Angiography Gerretsen et al
 Contrast ratio =
vessel muscle
gb muscle
vessel musclegp
muscle
SI SI
CNR SD
CNR SI SI
SD
? ??? ?? ?? ? ??? ?? ?
 
 and vessel-to-background signal 
ratio = 
vessel
muscle gadobenate dimeglumine
vessel
muscle gadopentetate dimeglumine
SI
SD
SI
SD
? ?? ?? ?
? ?? ?? ?
,
 
 where  CNR gb and  CNR gp are the CNRs 
of gadobenate dimeglumine and ga-
dopentetate dimeglumine, respectively; 
 SI vessel and  SI muscle are the mean vessel 
and muscle SIs, respectively; and 
 SD muscle is the standard deviation of the 
muscle SI. 
 Diagnostic Performance 
 Digital subtraction angiography.— The 
96 enrolled patients included 31 who 
underwent both contrast-enhanced MR 
angiography and conventional DSA. 
DSA was performed 1–110 days before 
the fi rst contrast-enhanced MR an-
giographic examination or 1–221 days 
after the second contrast-enhanced 
MR angiographic examination by in-
jecting an iodinated contrast medium 
through a pigtail or straight 4–5-F cath-
eter (Cordis, Miami, Fla) inserted via 
a femoral artery puncture by using the 
Seldinger technique. The approach to 
DSA was at the discretion of the inves-
tigating center and involved imaging in 
one (13 patients) or both (18 patients) 
legs. Pelvic images were acquired by us-
ing anteroposterior and right and/or left 
anterior oblique projections at angula-
tions of 15°–30°, as appropriate. Most 
examinations were performed by using 
contrast media with iodine concentra-
tions of more than 300 mg of iodine 
per milliliter. The total volume adminis-
tered ranged between 100 and 150 mL. 
Individual injections of 15–40 mL were 
administered at rates of 4–12 mL/sec, 
depending on the vessel of interest. 
 Assessment of diagnostic perfor-
mance.— Evaluation of DSA images was 
performed by a radiologist (C.E.M.B., 
teries), and calf (left and right tibiofi bu-
lar trunks, left and right anterior and 
posterior tibial arteries, and left and 
right peroneal arteries). 
 Qualitative assessments were per-
formed for vessel anatomic delineation 
and pathologic feature detection/exclu-
sion. Both comparisons were performed 
by using three-point scales, rated as  2 1 
(examination 1 was superior), 0 (exam-
inations were equal), or 1 (examination 
2 was superior). 
 Quantitative measurements of sig-
nal intensity (SI) were performed for 
regions of interest positioned on each 
of three vessels and three muscles (one 
each per station) in each patient. Re-
gions of interest were typically circular 
and large enough (  0.5 cm 2 ) to ob-
tain reliable measurements at areas of 
maximum SI in the vessel lumen and on 
homogenous regions of muscle. Region 
of interest positioning was similar for 
the two examinations in each patient. 
SI measurements were obtained on a 
pixel-by-pixel basis by using quantitative 
analysis software (Aquarius Net Server, 
version 1.8.3.6; TeraRecon). 
 Absolute values for SNR and 
contrast-to-noise ratio (CNR) were not 
determined because of the variable use 
of parallel imaging across the investiga-
tional centers. Therefore, quantitative 
enhancement was compared in terms of 
contrast ratio and vessel-to-background 
signal ratio, which were calculated by 
using the following equations: 
contrast-enhanced MR angiography) 
who were blinded to the contrast agent 
used. Evaluation of each station was 
performed initially for technical ad-
equacy (adequate or inadequate; ie, 
stations were inadequate if they were 
outside the scanning volume or if the 
acquisition was mistimed). Adequate 
image sets were thereafter assessed for 
vessel visualization quality at each sta-
tion by using a four-point scale in which 
1 = poor, 2 = suffi cient, 3 = good, and 
4 = excellent visualization. 
 Offsite assessment.— Offsite assess-
ments were performed by three inde-
pendent radiologists (A.V., J.V., and 
M.N.W., each with   10 years experience 
with contrast-enhanced MR angiog-
raphy) who were unaffi liated with the 
study sites and blinded to patient in-
formation and contrast agent. Images 
were evaluated in matched pairs; in 
each case, axial source images and vol-
umetric maximum intensity projection 
reconstructions from the two exami-
nations in each patient were displayed 
simultaneously on two workstations 
(AquariusNet Viewer for Windows; 
TeraRecon, San Mateo, Calif). 
 Evaluations were performed by us-
ing an arterial segmentation scheme 
comprising 23 arterial segments across 
the pelvis (aortic bifurcation and left 
and right common, internal, and exter-
nal iliac arteries), thigh (left and right 
common, superfi cial, and deep femoral 
arteries and left and right popliteal ar-
 Table 1 
 Range of Sequence Parameters by Vascular Station 
Parameter Pelvic Station Thigh Station Calf Station
Repetition time (msec) * 2.5, 4.2 2.5, 5.0 2.9, 5.1
Echo time (msec) * 1.0, 1.3 1.0, 1.5 1.0, 1.6
Flip angle (degrees) * 15, 40 15, 40 15, 40
Number of signals * 1, 1 1, 1 1, 1
Minimum fi eld of view 470  3 264  3 78 470  3 306  3 61 448  3 278  3 91
Maximum fi eld of view 470  3 353  3 848 451  3 512  3 180 451  3 316  3 256
Acquisition matrix * 336  3 180, 512  3 250 336  3 180, 384  3 308 202  3 384, 480  3 480
No. of sections/partitions * 52, 104 51, 88 60, 160
Parallel acquisition factor * 2, 2 2, 2 0, 3
Section thickness (mm) * 2, 3 1, 3 1, 2
Acquisition time (sec) * 11, 18 11, 19 11, 96
* Data are the minimum followed by the maximum values.
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with 86 (90%) with moderate-to-severe 
claudication (Fontaine stage IIb [ 33 ]), 
fi ve (5%) with ischemic rest pain (Fon-
taine stage III), and fi ve (5%) with 
ulceration (Fontaine stage IV). Most 
subjects underwent contrast-enhanced 
MR angiography to confi rm or evaluate 
a previously detected stenosis (43 of 
96, 45%) or because of clinical symp-
toms suggestive of stenosis (45 of 96, 
47%). Eight (8%) subjects underwent 
contrast-enhanced MR angiography to 
guide revascularization or as follow-up 
to a previous treatment. 
 The patients were randomized to 
group A (33 men, 19 women; mean age, 
63.4 years  6 10.4) or B (29 men, 15 
women; mean age, 64.0 years  6 10.5) 
( Fig 1 ). There were no between-group 
differences in sex distribution ( P = 
.803), age ( P = .748), weight ( P = .795), 
or Fontaine stage ( P = .463). Overall, 
92 (96%) of 96 patients received both 
agents. Four patients (two from each 
group) discontinued prematurely after 
the fi rst examination. On-site assess-
ment of technical adequacy and safety 
was performed for all patients who re-
ceived at least one contrast agent ( n = 
94 for both contrast agents). 
 The 31 patients with DSA comprised 
17 from group A and 14 from group B. 
Twenty-six patients were classifi ed with 
Fontaine stage IIb disease while three 
and two patients classifi ed with Fon-
taine stages III and IV, respectively. 
There were no between-group differ-
ences in sex distribution ( P = .566), age 
( P = .744), weight ( P = .927), or Fon-
taine stage ( P = .903). 
 On-Site Assessments 
 Technical failure rate.— A total of 564 
stations were assessed (188 + 188 + 
188; pelvis, thigh, and calf measure-
ments) across the 94 patients who re-
ceived at least one contrast agent. Over-
all, signifi cantly fewer stations were 
technically inadequate after gadobenate 
dimeglumine than after gadopentetate 
dimeglumine (20 of 564, 3.5% vs 67 of 
564, 11.9%;  P  , .0001,  Table 2 ). 
 Vessel visualization quality.— Superior 
vessel visualization quality was noted 
with gadobenate dimeglumine at each 
station ( P  , .0001) ( Table 3 ). Overall, 
specifi ed proportions in three catego-
ries performed with software (nQuery, 
version 5.0; Statistical Solutions, Cork, 
Ireland), 78 subjects were needed for 
80% of power at an  a level of .05. As-
suming a 30% dropout rate, enrolment 
of 100 subjects was required. 
 Contrast-enhanced MR angiography 
technical failure rates and vessel visu-
alization quality were assessed overall 
and at each station by using the  x 2 and 
Wilcoxon rank-sum tests, respectively. 
Comparison of vessel anatomic delinea-
tion and pathologic feature detection/
exclusion were performed by using the 
Wilcoxon signed-rank test. Comparison 
of quantitative enhancement was per-
formed by using a mixed model with 
subject, period, sequence, and contrast 
agent group as variables. 
 Determinations of diagnostic perfor-
mance (sensitivity, specifi city, accuracy, 
positive predictive value [PPV], nega-
tive predictive value [NPV], and 95% 
confi dence intervals) for the detection 
of clinically relevant disease ( . 50% 
stenosis or occlusion) ( 31–33 ) were 
performed as described elsewhere ( 34 ). 
Differences in sensitivity, specifi city, and 
accuracy were compared by using the 
McNemar test. Differences in PPV and 
NPV were compared by using the Wald 
test, derived from a generalized esti-
mating equation, with intraindividual 
correlation accounted for. 
 Interreader agreement was deter-
mined by using generalized weighted  k 
statistics and measured as a percentage 
agreement. Agreement was classifi ed 
as excellent ( k  . 0.8), good ( k = 0.61–
0.8), moderate ( k = 0.41–0.6), fair ( k = 
0.21–0.4), or poor ( k   0.2) ( 35 ). All 
statistical tests were two-sided, with a 
 P value of less than .05 indicating a sig-
nifi cant difference and were performed 
by using dedicated software (SAS, ver-
sion 8.2; SAS, Cary, NC). 
 Results 
 There were 96 patients enrolled (mean 
age, 63.7 years  6 10.4 [standard devia-
tion]; range, 39–86 years), including 62 
men (mean age, 64.3 years  6 9.4; range, 
39–86 years) and 34 women (mean age, 
61.2 years  6 11.7; range, 40–81 years), 
with  . 10 years experience) who was un-
affi liated with the study centers and 
blinded to all clinical and radiologic in-
formation. Images were managed and 
displayed in random order by using soft-
ware (DICOMed Review, version 4.0; 
AetMed, Genova, Italy). The presence 
and extent of disease were determined 
for each segment by using a four-point 
scale: a score of 1, segment has no or 
mild stenosis (  25%); 2, segment has 
moderate stenosis ( . 25% but   50%); 
3, segment has clinically relevant disease 
( . 50%–99%); and 4, segment has occlu-
sion (100% lumen blockage). Stenoses 
detected at DSA were labeled for sub-
sequent lesion matching. 
 Assessment of contrast-enhanced 
MR angiograms was thereafter per-
formed by the offsite radiologists. Im-
ages were randomized and evaluated 
separately and independently in blinded 
fashion by using the same criteria as 
those used for the assessment of DSA 
images. Stenoses detected at contrast-
enhanced MR angiography were labeled 
on maximum intensity projection images 
for subsequent lesion matching. 
 Safety Assessments 
 The 96 subjects were monitored for 
adverse events from the time informed 
consent was obtained until 24 hours 
after administration of the fi rst con-
trast agent, and then from 24 hours 
before and until 24 hours after ad-
ministration of the second contrast 
agent. Events were classifi ed as seri-
ous (death, life-threatening, requiring/
prolonging hospitalization) or nonse-
rious (mild: no disability/incapacity, 
self-resolving; moderate: no disability/
incapacity requiring treatment; or se-
vere: temporary and/or mild disability/
incapacity requiring treatment). Event 
severity and its relationship to the con-
trast agent (probable, possible, unre-
lated, or unknown) were determined 
by the investigating radiologist. 
 Statistical Analysis 
 The study was powered to show a 3:1 
ratio of superiority for either contrast 
agent with an effect size of 0.125 and 
assuming an equal response in 50% of 
cases. Given the results of a  x 2 test of 
Radiology: Volume 255: Number 3—June 2010 n radiology.rsna.org 993
 VASCULAR AND INTERVENTIONAL RADIOLOGY: Contrast Material Comparison for MR Angiography Gerretsen et al
55.4%–100.6% (thigh), and 49.2%–
66.5% (calf) were obtained with ga-
dobenate dimeglumine compared with 
gadopentetate dimeglumine. The corre-
sponding contrast ratios for gadobenate 
dimeglumine relative to gadopentetate 
dimeglumine ranged from 1.45 to 1.6 
(pelvis), 1.55 to 2.0 (thigh), and 1.49 
to 1.67 (calf). Signifi cant increases 
( P  , .0001) in vessel-to-background 
signal were similarly obtained with rela-
tive increases of 44.7%–55.0% (pelvis), 
49.3%–90.9% (thigh), and 43.0%–
58.1% (calf), corresponding to vessel-
to-background signal ratios per patient 
of 1.42–1.55 (pelvis), 1.49–1.91 (thigh), 
and 1.43–1.58 (calf). 
 Diagnostic performance.— A total 
of 397 vascular segments were assessed 
across the 31 evaluated patients. DSA 
helped show clinically relevant disease 
in 127 (32.0%) of 397 segments. Each 
blinded reader reported signifi cantly 
better ( P   .0017) diagnostic perfor-
mance with gadobenate dimeglumine 
than with gadopentetate dimeglumine 
(increases of 11.0%–18.1% in sensitivity, 
4.4%–9.3% in specifi city, and 7.8%–
10.1% in accuracy) ( Table 5 ;  Fig 4 ). 
Each reader also reported signifi cantly 
higher ( P   .0028) predictive values 
with gadobenate dimeglumine, with dif-
ferences ranging from 12.7% to 19.3% 
for PPV and 5.5% to 7.9% for NPV. 
 Good to excellent reader agreement 
for stenosis detection and grading was 
noted. All three readers agreed on 591 
(90.2%) of 655 segments assessed on 
gadobenate dimeglumine–enhanced im-
ages ( k = 0.805) compared with 529 
(87.6%) of 604 segments assessed on 
gadopentetate dimeglumine–enhanced 
images ( k = 0.749). 
 Safety.— Six adverse events (three 
reports of dizziness and one report 
each of nausea, dysgeusia, and pruri-
tus) were reported by four (4%) pa-
tients after gadobenate dimeglumine 
compared with eight adverse events 
(one report each of eye irritation, nau-
sea, vomiting, chest pain, heat sensa-
tion, dizziness, dysgeusia, and hyper-
hidrosis) reported by fi ve (5%) patients 
after gadopentetate dimeglumine. All 
adverse events were nonserious and 
mild in intensity. 
compared with 24 (4.3%) stations when 
using gadobenate dimeglumine. 
 Off-Site Assessments 
 Qualitative.— Gadobenate dimeglumine 
improved vessel anatomic delinea-
tion and pathologic feature detection/
exclusion at each station ( Table 4 ,  Fig 3 ; 
 P  , .0001). Three-reader agreement 
was noted for 48–63 (52.7%–70.0%) 
patients across both endpoints at all 
vascular stations, resulting in a general-
ized  k of 0.37–0.44. 
 Quantitative.— Signifi cant increases 
( P  , .0001; all readers, all evalua-
tions) in CNR of 45.0%–59.6% (pelvis), 
491 (87.06%) of 564 evaluated stations 
were of good or excellent image quality 
when using gadobenate dimeglumine 
compared with 413 (73.49%) of 562 
stations when using gadopentetate di-
meglumine. The quality of visualization 
was poor primarily for vessels in the 
calf (9.6% and 20.2% of vessels after 
gadobenate dimeglumine and gadopen-
tetate dimeglumine administration, re-
spectively) ( Fig 2 ), and for vessels in 
the pelvis and thigh after gadopentetate 
dimeglumine (6.9% and 14.0% of ves-
sels, respectively). Overall, 77 (13.7%) 
stations were of poor image quality 
when using gadopentetate dimeglumine 
 Table 2 
 Technical Failure Rates for Contrast-enhanced MR Angiography 
Vascular Station
Gadobenate Dimeglumine Gadopentetate Dimeglumine
 P Value * 
Technically 
Inadequate 
Stations
Technical Failure 
Rate (%)
Technically 
Inadequate 
Stations
Technical Failure 
Rate (%)
Pelvis ( n = 188) 2 1.06 11 5.85 .0111
Thigh ( n = 188) 1 0.53 24 12.77  , .0001
Calf ( n = 188) 17 9.04 32 17.02 .0216
All stations ( n = 564) 20 3.55 67 11.88  , .0001
Note.—Examinations were performed with gadobenate dimeglumine and gadopentetate dimeglumine at equivalent doses of 
0.1 mmol/kg, as determined by on-site investigators.
 * Determined by using the  x 2 test.
 Table 3 
 Unpaired (On-site) Assessments of Quality of Vessel Visualization 
Vascular Station and Contrast Agent
Quality Score
 P Value1 (Poor) 2 (Suffi cient) 3 (Good) 4 (Excellent)
Pelvis
 Gadobenate dimeglumine 3 (1.6) 9 (4.8) 39 (20.7) 137 (72.9)  , .0001
 Gadopentetate dimeglumine 13 (6.9) 18 (9.6) 61 (32.4) 96 (51.1)
Thigh
 Gadobenate dimeglumine 3 (1.6) 11 (5.9) 37 (19.7) 137 (72.9)  , .0001
 Gadopentetate dimeglumine  * 26 (14.0) 22 (11.8) 37 (19.9) 101 (54.3)
Calf
 Gadobenate dimeglumine 18 (9.6) 29 (15.4) 59 (31.4) 82 (43.6)  , .0001
 Gadopentetate dimeglumine 38 (20.2) 32 (17.0) 63 (33.5) 55 (29.3)
All
 Gadobenate dimeglumine 24 (4.3) 49 (8.7) 135 (23.9) 356 (63.1)  , .0001
 Gadopentetate dimeglumine 77 (13.7) 72 (12.8) 161 (28.6) 252 (44.8)
Note.—Data are number of vessel segments; percentages are in parentheses.
* Left and right images of the thigh were missing for one patient given gadopentetate dimeglumine, owing to a scanner 
reconstruction problem. This image set was considered technically inadequate and no assessment was performed for quality of 
visualization; therefore, only 186 thigh stations were assessed for this contrast agent.
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cally relevant stenoses were signifi cantly 
superior ( P   .0017) with gadobenate 
dimeglumine for each reader. 
 In terms of diagnostic accuracy, 
our values for gadobenate dimeglumine 
compare favorably with values from 
meta-analyses ( 31–33 ) and imply that 
correct patient management decisions 
are achievable in approximately 90% 
of cases. In comparison, the accuracy 
with 0.1 mmol/kg of gadopentetate di-
meglumine was signifi cantly lower ( P  , 
.0001). In part, the poorer diagnostic 
performance with gadopentetate dime-
glumine can be ascribed to the dose 
 Discussion 
 Our study confi rms previous fi ndings 
( 28 ) in showing that a dose of 0.1 
mmol/kg of gadobenate dimeglumine 
is superior to an equivalent dose of ga-
dopentetate dimeglumine for contrast-
enhanced MR angiography in patients 
with peripheral arterial occlusive dis-
ease. Three blinded readers each re-
ported better vessel anatomic delinea-
tion and improved detection/exclusion 
of pathologic features in signifi cantly 
more ( P  , .0001) patients with gado-
benate dimeglumine. In addition, the 
detection and correct grading of clini-
 Figure 2 
  
 Figure 2: MR images (repetition time msec/echo 
time msec, 3.1/1.1; fl ip angle, 25° [pelvis]; 3.5/1.2; 
fl ip angle, 25° [thigh]; and 3.5/1.2; fl ip angle, 25° 
[calf]) in 72-year-old man show moderate claudication 
in right and left thigh and calf (Fontaine stage IIb) after 
administration of 0.1 mmol/kg of  (a) gadobenate di-
meglumine, and  (b) gadopentetate dimeglumine. More 
homogeneous contrast enhancement with gadobenate 
dimeglumine results in better visualization of peripheral 
arterial vasculature and better depiction of vascular 
disease. Also, better delineation of plaque formation 
in aortic bifurcation (arrowhead,  a ) extending to both 
iliac arteries and clearer depiction of extent of stenosis 
(arrow) in left common iliac artery is achieved, relative 
to  (c) corresponding DSA image. Better enhancement 
of thigh station with gadobenate dimeglumine allows 
exclusion of signifi cant stenosis (arrow) in right com-
mon femoral artery, while multiple stenoses (arrows) in 
left superfi cial femoral artery are better seen. Posterior 
tibial artery can be followed to foot (arrow); patent bi-
furcation (arrow) of peroneal and anterior tibial arteries 
is more clearly seen with gadobenate dimeglumine. 
administered; in routine practice, con-
ventional controst agents such as gado-
pentetate dimeglumine are typically used 
at higher doses of up to 0.3 mmol/kg 
( 13,31,37,38 ). Although a study that 
compared single and triple doses of ga-
dodiamide for contrast-enhanced MR 
angiography of the lower extremities 
revealed more accurate stenosis grad-
ing with the lower dose ( 7 ), a study that 
compared 0.1-mmol/kg doses of gadodi-
amide and gadopentetate dimeglumine 
for detection of clinically relevant aor-
toiliac disease determined overall accu-
racy values of just 56.4% and 52.8%, 
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renal to the popliteal arteries. However, 
rather than adopt an intraindividual 
crossover study design as utilized here, 
Wyttenbach et al used an interindi-
vidual parallel group design and higher 
overall doses of contrast agent. On the 
one hand, an interindividual study de-
sign is subject to variability between 
study groups, which may have affected 
( 40–46 ) have similarly revealed im-
proved performance with gadobenate 
dimeglumine when comparisons are 
performed at equivalent dose levels. 
Interestingly however, Wyttenbach et al 
( 29 ) noted few differences between ga-
dobenate dimeglumine and gadoterate 
meglumine for assessment of periph-
eral arterial occlusive disease from the 
respectively ( 8 ). In that study, the poor 
diagnostic performance with both con-
trast agents was attributed to the rela-
tively low doses administered. Other 
studies that have compared gadobenate 
dimeglumine with gadopentetate dime-
glumine and other conventional agents 
for contrast-enhanced MR angiography 
( 26–28,38,39 ) and other applications 
 Table 5 
 Diagnostic Performance of MR Angiography of Peripheral Arterial Vasculature 
Contrast Agent Sensitivity Specifi city Accuracy Positive Predictive Value Negative Predictive Value
Reader 1
 Gadobenate 
 dimeglumine
75.6 (96/127) 
   [68.1, 83.1]
95.9 (259/270) [93.5, 98.3] 89.4 (355/397) 
   [86.4, 92.4]
89.7 (96/107) [83.9, 95.5] 89.3 (259/290) [85.7, 92.9]
 Gadopentetate 
 dimeglumine
60.6 (77/127) 
   [52.1, 69.1]
91.5 (247/270) [88.2, 94.8] 81.6 (324/397) 
   [77.8, 85.4]
77.0 (77/100) [68.8, 85.2] 83.2 (247/297) [78.9, 87.5]
  P Value  P  , .0001 [8.4, 21.5]  P = .0005 [2.0, 6.9]  P  , .0001 [5.1, 10.5]  P = .0016 [2.6, 22.8]  P  , .0001 [0.1, 11.6]
Reader 2
 Gadobenate 
 dimeglumine
80.3 (102/127) 
   [73.4, 87.2]
95.9 (259/270) [93.5, 98.3] 90.9 (361/397) 
   [88.1, 93.7]
90.3 (102/113) [84.8, 95.8] 91.2 (259/284) [87.9, 94.5]
 Gadopentetate 
 dimeglumine
69.3 (88/127) 
   [61.3, 77.3]
86.7 (234/270) [82.7, 90.8] 81.1 (322/397) 
   [77.2, 85.0]
71.0 (88/124) [63.0, 79.0] 85.7 (234/273) [81.5, 89.9]
  P Value  P = .0017 [4.4, 17.7]  P  , .0001 [4.9, 13.7]  P  , .0001 [6.2, 13.5]  P = .0019 [9.6, 29.0]  P = .0009 [0.2, 10.8]
Reader 3
 Gadobenate 
 dimeglumine
82.7 (105/127) 
   [76.1, 89.3]
95.9 (259/270) [93.5, 98.3] 91.7 (364/397) 
   [89.0, 94.4]
90.5 (105/116) [85.2, 95.8] 92.2 (259/281) [89.1, 95.3]
 Gadopentetate 
 dimeglumine
64.6 (82/127) 
   [56.3, 72.9]
89.6 (242/270) [86.0, 93.2] 81.6 (324/397) 
   [77.8, 85.4]
74.5 (82/110) [66.4, 82.6] 84.3 (242/287) [80.1, 88.5]
  P Value  P  , .0001 [10.4, 25.8]  P = .0016 [2.5, 10.1]  P  , .0001 [6.4, 13.7]  P = .0028 [6.3, 25.7]  P = .0008 [2.7, 13.1]
Note.—Data are percentages; raw numbers are in parentheses; 95% confi dence intervals are in square brackets. Analysis was performed per segment; the denominator was the number of segments 
visualized by using DSA. All uninterpretable contrast-enhanced MR angiograms were considered inaccurate for all determinations. Signifi cant differences in sensitivity, specifi city, and accuracy were 
determined by using the McNemar test. Signifi cant differences in positive and negative predictive values were determined by using the Wald test. Differences and their confi dence intervals for 
sensitivity, specifi city, and accuracy are estimated by using a paired binary approach. The confi dence intervals for sensitivity, specifi city, accuracy, negative and positive predictive values and the 
differences in them are calculated given a normal approximation of binomial distribution.
 Table 4 
 Qualitative Comparison Assessment by Off-Site Readers 
Parameter 
Pelvis ( n = 91) Thigh ( n = 90) Calf ( n = 91)
Gadobenate 
Dimeglumine
Gadopentetate 
Dimeglumine
Gadobenate 
Dimeglumine
Gadopentetate 
Dimeglumine
Gadobenate 
Dimeglumine
Gadopentetate 
Dimeglumine
Vessel anatomic delineation
 Reader 1 59 (64.8) 11 (12.1) 66 (73.3) 5 (5.6) 60 (65.9) 3 (3.3)
 Reader 2 52 (57.1) 6 (6.6) 70 (77.8) 3 (3.3) 63 (69.2) 5 (5.5)
 Reader 3 61 (67.0) 6 (6.6) 75 (83.3) 8 (8.9) 62 (68.1) 8 (8.8)
Pathologic feature detection/
 exclusion
 Reader 1 45 (49.5) 8 (8.8) 52 (57.8) 1 (1.1) 49 (53.8) 0
 Reader 2 42 (46.2) 5 (5.5) 61 (67.8) 3 (3.3) 56 (61.5) 4 (4.4)
 Reader 3 43 (47.3) 6 (6.6) 60 (66.7) 6 (6.7) 55 (60.4) 7 (7.7)
Note.—Qualitative comparison performed when one contrast agent was rated higher than the other for vessel delineation and pathologic feature detection/exclusion.
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mine have been shown as deleterious in 
terms of image quality and diagnostic 
performance ( 9,47,48 ). Notably, a 0.1-
mmol/kg dose of gadobenate dimeglu-
mine provides similar image quality and 
contrast enhancement to that achieved 
with a double 0.2-mmol/kg dose of ga-
dopentetate dimeglumine for contrast-
enhanced MR angiography of the renal 
arteries and abdominal aorta ( 26 ) and 
carotid arteries ( 27 ). 
 Of particular relevance for routine 
practice were the low technical failure 
rate and improved image quality in the 
calves. Similar fi ndings have been noted 
by Knopp et al ( 28 ) and Wyttenbach 
et al ( 29 ), despite the higher dose used 
in the latter study. In terms of diagnos-
tic performance, a recent multicenter 
Phase III study that used a dose of 0.1 
mmol/kg of gadobenate dimeglumine 
revealed diagnostic accuracy values of 
85.0%–87.5% in the iliofemoral arter-
ies and 74.5%–77.5% in the calf arteries 
( 34 ). Conversely, assessment of below-
knee arteries was not performed in 
equivalent Phase III studies with other 
contrast agents at doses of 0.1 mmol/kg 
or less ( 8,49,50 ). Given that the quality 
of calf vessel visualization in our study 
was poor in signifi cantly more patients 
after 0.1 mmol/kg gadopentetate di-
meglumine than after 0.1 mmol/kg 
gadobenate dimeglumine, it is possible 
that worse overall results might have 
been obtained in these other studies 
had below-knee vessels been included 
in the assessment. More importantly, 
the comparatively poor quality of ves-
sel visualization with gadopentetate di-
meglumine in our study and elsewhere 
( 28,29 ), particularly for below-knee 
arteries, would necessitate a repeat 
examination with associated increased 
costs. 
 An unfortunate consequence of the 
large number of sites involved in our 
study was a variable approach to the 
use of parallel imaging. Since local 
fi eld inhomogeneities are known to af-
fect SI determinations if parallel imaging 
techniques are utilized ( 51,52 ), it was 
deemed inappropriate to calculate abso-
lute SNR and CNR values. Nevertheless, 
the determinations of contrast ratio and 
vessel-to-background signal ratio  confi rm 
 Figure 3 
  
 Figure 3: MR images (3.0/1.1; fl ip angle, 25° [pelvis]; 2.9/1.0; fl ip angle, 
25° [thigh]; and 3.0/1.1; 25° [calf]) in 68-year-old man show moderate 
claudication in right and left calf (Fontaine stage IIb) after administration of 0.1 
mmol/kg of  (a) gadobenate dimeglumine, and  (b) gadopentetate dimeglumine. 
Although on-site investigators considered quality of vessel visualization as ex-
cellent across all territories in both limbs for both agents, contrast enhancement 
obtained with gadobenate dimeglumine is much more homogeneous, with no 
decrease of signal intensity at boundaries between acquisition steps (arrows,  b ). 
Also, small vessels are more clearly seen with gadobenate dimeglumine, with 
better depiction of small arteries in popliteal area (arrow,  a ). 
the overall fi ndings; on the other hand, 
the higher doses used may have been 
appropriate for gadoterate meglumine 
but disadvantageous for gadobenate di-
meglumine. In this regard, higher doses 
of 0.2 mmol/kg of gadobenate dimeglu-
Radiology: Volume 255: Number 3—June 2010 n radiology.rsna.org 997
 VASCULAR AND INTERVENTIONAL RADIOLOGY: Contrast Material Comparison for MR Angiography Gerretsen et al
 Figure 4 
  
 Figure 4:  MR images in 74-year-old man show moderate claudication in right and left calf (Fontaine IIb) after  (a,b) gadobenate 
dimeglumine, and  (c,d) gadopentetate dimeglumine. On-site vessel visualization was excellent in pelvis and thigh and good in 
calf after gadobenate dimeglumine and good at all stations after gadopentetate dimeglumine.  (e) DSA shows complete occlusion 
(upper arrow) of superfi cial femoral artery and multiple collateral vessels (lower arrows), both of which are visible with both contrast 
agents. Greater detail is apparent on  a and  b , as evidenced by collateral vessel just proximal to occlusion, which shows very good 
correlation with DSA.  (f) Calf DSA shows high-grade stenosis (upper arrow) at origin of posterior tibial artery and moderate stenosis 
(lower arrow) of peroneal artery. Good correlation for both stenoses was noted for  a and  b ; underestimation of stenosis and poorer 
overall image quality were apparent for  c and  d . 
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previous fi ndings ( 26–28,38,40–44 ) in 
showing greater quantitative enhance-
ment with gadobenate dimeglumine. 
 One limitation of our study was that 
assessments were not performed in the 
foot. Ischemic disease of the foot is an 
important complication of peripheral 
arterial occlusive disease, particularly 
in the diabetic population, and accurate 
assessment of the pedal vessels is nec-
essary for possible revascularization or 
bypass procedures ( 53 ). The foot was 
not evaluated primarily because it is of-
ten not indicated in patients with inter-
mittent claudication only, and because 
examination of the entire arterial vas-
culature from the pelvis to the foot is 
not yet a widely used procedure owing 
to technical diffi culties associated with 
acquisition over large anatomic areas. 
 Other limitations were that state-of-
the-art sequences and hardware were 
not utilized at all centers and that a 
diagnostic reference standard was not 
available for all patients. Concerning 
the imaging parameters utilized, these 
were a refl ection of the multicenter 
study design and the fact that not all 
centers were equipped with advanced 
hardware. On the other hand, the se-
quences used were those used routinely 
at the individual centers and thus the 
results may refl ect those that might be 
obtained routinely at similarly equipped 
centers. Concerning the lack of a ref-
erence standard for all patients, this 
refl ects the fact that contrast-enhanced 
MR angiography has fully replaced 
DSA at most centers for purely diag-
nostic imaging. The fact that DSA was 
performed in only 31 patients indi-
cates that the contrast-enhanced MR 
angiography fi ndings were invariably 
considered adequate for subsequent 
patient treatment decisions. However, 
it should be kept in mind that the ab-
sence of DSA performed in all other 
patients is a potential source of bias 
for determinations of diagnostic perfor-
mance because patients without abnor-
malities seen at contrast-enhanced MR 
angiography are typically not referred 
for DSA. Thus, the assessment of diag-
nostic performance is based on only a 
subset of patients with severe disease 
( 54 ). It should also be kept in mind that 
the diagnostic accuracy achieved with 
gadobenate dimeglumine was signifi -
cantly greater ( P  , .0001) among the 
subgroup of patients for whom accurate 
diagnosis is most critical. 
 In summary, this study demon-
strates that image quality and diagnos-
tic accuracy for the detection of clinically 
relevant peripheral arterial occlusive 
disease are signifi cantly improved at 
peripheral contrast-enhanced MR an-
giography with a dose of 0.1 mmol/kg 
of gadobenate dimeglumine compared 
with a dose of 0.1 mmol/kg of gadopen-
tetate dimeglumine. 
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